Israel · Delayed Price · Currency is ILS · Price in ILA Enlivex Therapeutics Statistics
Total Valuation
TLV:ENLV has a market cap or net worth of ILS 77.99 million. The enterprise value is 18.26 million.
| Market Cap | 77.99M |
| Enterprise Value | 18.26M |
Important Dates
The next estimated earnings date is Friday, November 28, 2025.
| Earnings Date | Nov 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 24.29M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +21.10% |
| Shares Change (QoQ) | +0.41% |
| Owned by Insiders (%) | 4.52% |
| Owned by Institutions (%) | 5.25% |
| Float | 23.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.35 |
| P/TBV Ratio | 1.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.43 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.46 |
Financial Position
The company has a current ratio of 6.43
| Current Ratio | 6.43 |
| Quick Ratio | 6.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -57.64% and return on invested capital (ROIC) is -40.76%.
| Return on Equity (ROE) | -57.64% |
| Return on Assets (ROA) | -36.02% |
| Return on Invested Capital (ROIC) | -40.76% |
| Return on Capital Employed (ROCE) | -81.64% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.95% in the last 52 weeks. The beta is 1.48, so TLV:ENLV's price volatility has been higher than the market average.
| Beta (5Y) | 1.48 |
| 52-Week Price Change | -19.95% |
| 50-Day Moving Average | 347.26 |
| 200-Day Moving Average | 378.61 |
| Relative Strength Index (RSI) | 39.35 |
| Average Volume (20 Days) | 27,640 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -48.41M |
| Pretax Income | -42.05M |
| Net Income | -42.05M |
| EBITDA | -47.44M |
| EBIT | -48.41M |
| Earnings Per Share (EPS) | -1.79 |
Balance Sheet
The company has 60.27 million in cash and n/a in debt, giving a net cash position of 60.27 million.
| Cash & Cash Equivalents | 60.27M |
| Total Debt | n/a |
| Net Cash | 60.27M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 57.88M |
| Book Value Per Share | 2.38 |
| Working Capital | 54.52M |
Cash Flow
In the last 12 months, operating cash flow was -39.32 million and capital expenditures -314,555, giving a free cash flow of -39.63 million.
| Operating Cash Flow | -39.32M |
| Capital Expenditures | -314,555 |
| Free Cash Flow | -39.63M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TLV:ENLV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.10% |
| Shareholder Yield | -21.10% |
| Earnings Yield | -53.92% |
| FCF Yield | -50.81% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |